Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HER2-Positive Solid Tumors: Molecule Exhibits Antitumor Activity

Publish date:: November 11, 2019

Key clinical point: PRS-343, a 4-1BB/HER2 bispecific molecule, demonstrated antitumor activity in patients with heavily pretreated, HER2-positive solid tumors.

Major finding: Of 18 evaluable patients, 2 achieved a partial response and 8 had stable disease.

Study details: A phase 1 study of 53 patients.

Disclosures: The study is sponsored by Pieris Pharmaceuticals. Dr. Ku disclosed relationships with Arog Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck, Zymeworks, and Pieris Pharmaceuticals.

Citation:

Ku GY et al. SITC 2019, Abstract O82.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,